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Abstract: 
Objective  
To explore amateur endurance athletes’ use and views about non-
steroidal anti-inflammatory drugs (NSAIDs)  
 
Methods  
An online cross-sectional survey of amateur athletes at 4 athletic clubs.  
 
Key findings  
Of a sample of 129 of amateur athletes, 68% (n=88) reported using 
NSAIDs in the previous 12 months (84.4% in triathletes, 70.9% in 
runners, and 52.5% in cyclists). Overall, ibuprofen was the most 
popular drug (n=48). There was a lack of knowledge of adverse drug 
reactions, with only 26% of use advised by a doctor or pharmacist.  
 
Conclusions  
There is high usage of NSAIDs in amateur athletes, including before and 
during events, largely without professional health advice. Informational 
needs of amateur athletes are not being met.  
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Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) are used by athletes (1-4) and are widely available 
over-the-counter in the UK. They are for control of injury pain, pain during training and events, and 
pain post intense effort (such as delayed onset muscle soreness).(5) Although not listed on the World 
Anti-Doping Agency (WADA) list of prohibited substances, a recent review has suggested a 
performance enhancing effect by reducing the perception of effort and exercise-induced pain.(6) 
  
NSAIDs are associated with adverse effects, such as gastric ulcers, acute renal failure, and 
cardiovascular events.(7) Prophylactic use of NSAIDs prior to an endurance event has been associated 
with gastrointestinal and cardiovascular events.(3) Although NSAIDs are licenced for pain relief, and 
used for pain associated with exercise, NSAIDs are now suspected to be detrimental to muscle 
healing(5), suggesting the benefit/harm balance of their use associated with exercise needs review.  
  
In 2013, a coroner concluded that ibuprofen contributed to the death of a 23-year-old amateur runner 
at the Brighton Marathon. After ingesting ibuprofen prior and during the event, he fell ill at mile 16 of 
the marathon, dying of bowel ischaemia and gastrointestinal haemorrhage.(8) Although an anecdotal 
report, it is supported by known adverse effects of ibuprofen(5) and increased rates of gastrointestinal 
adverse effects in a marathon.(3) 
  
Current knowledge of pharmacoepidemiology in amateur athletes is limited, and mainly focused on 
elite performers.(5) We aimed to examine the usage patterns and knowledge of NSAIDs by amateur 
endurance athletes. 
  
Methods 
We developed an online questionnaire asking participants about their use of NSAIDs, their 
management of injuries, and knowledge of adverse events. Questions consisted of multiple answer 
questions, and numeric entry. Demographic information was also collected. This was piloted with a 
number (n=6) of amateur endurance athletes and pharmacists. The survey was communicated to 
members of four amateur athletic clubs (consisting of one cycling club, two running clubs, and one 
mixed athletic, running, and triathlete club) by the club organisers using their websites or email. 
Participants were informed that participation in the survey would be taken as consent to the survey. 
Ethical approval for this process was granted by the University of Birmingham’s Ethics Committee. 
Data analysis was carried out using IBM SPSS (Version 21.0, IBM Corp). 
  
Results 
There were 129 respondents, of whom 30% were female. The respondents had a mean age of 33 (age 
range 18-70). NSAID usage was 84% in triathletes, 71% in runners and 53% in cyclists (Table 1). 
There was no association between usage and age. There was a small gender difference in NSAID 
usage (female 75%, male 65.2%), but this was statistically insignificant.  
  
When respondents were able to name a specific NSAID, ibuprofen was the most popular drug used 
(n=48), followed by aspirin (n=11), diclofenac (n=7), naproxen (n=3), and celecoxib (n=1).  
  
Sixty-eight percent (n=88) of respondents reported using NSAIDs in the previous 12 months to treat 
sport-related aches and pains. NSAID usage was associated with occurrence of an injury in the past 
12 months (χ2 value 12.187, p<0.001). Forty-five percent of athletes (n=58) used NSAIDs 
immediately before or after an activity (runners 56%, triathletes 70%, and cyclists 33%). Eight 
respondents used NSAIDs during an event. 
  
Non-users and users of NSAIDs had similar knowledge of expected benefits and adverse effects of 
NSAIDs (Table 2). NSAID users had a higher rate of indigestion remedy use than non-users (27% 
and 17% respectively). Only 26% of NSAID use was informed by a doctor or pharmacist.  
  
Discussion 
This study shows a high use of NSAIDs usage by recreational/amateur athletes. There is higher use in 
runners and triathletes, compared to cyclists, logically a consequence of the lower impact nature of 
cycling compared to running.  
  
Limitations include the small sample size, which may reduce the representativeness of the findings to 
the wider endurance athlete community. Respondent bias may also over-estimate the use of NSAIDs, 
since non-users of NSAIDs may be less likely to engage with a survey of NSAID use. The method of 
survey distribution means an accurate response rate cannot be calculated. While these limitations 
impair the generalisability of this study, this paper provides some early data on amateur athletic use of 
NSAIDs. Further pharmacoepidemiology of NSAIDs in a larger national population of amateur 
athletes is needed. 
  
Other studies have shown 60% of triathletes (Study size, n=327) using NSAIDs(2), 59% of runners 
(Study size, n=3913) using NSAIDs at the Bonn Marathon (3), and 57% of runners (study size, 
n=109) at the London Marathon using NSAIDs.(4) Evidence of use of NSAIDs during an event we 
found is of concern, given the increased risk of adverse effects associated with longer endurance 
events. Not all users of NSAIDs in ourstudy were aware of the gastro-intestinal and renal effects of 
NSAIDs. 
  
Perceived benefits reported by study participants, such as reduced bowel movements and an anti-
emetic effect are unsupported by evidence. Others, such as the anti-inflammatory effect of NSAIDs, 
may reduce pain, but lengthen recovery times.(5) Advice on harm/benefit of NSAIDs given to athletes 
by health care professionals, coaches, and race event organisers about the use of NSAIDs should be 
revised. In particular, the risk of NSAIDs before and during endurance events should be clearly 
described. Changes in renal function have been shown in marathon runners taking NSAIDs prior to an 
event (9) Additional consequences of NSAID use exist in the context of endurance sports; runners in 
endurance events have been found to be at increased risk of hyponatraemia (10). The prevalence of 
NSAID use found in this study found prior to events and during events, and the lack of professional 
advice received, highlight that greater information needs to beprovided to the amateur athletic 
population.  
  
Conclusion 
This study shows high usage of NSAIDs in amateur athletes, similar to previous studies in elite 
athletes. As might be expected usage is associated with injuries, but also before and during events 
when the risks of NSAIDs may be heightened due to increased physiological stresses. Despite 
limitations in generalisability, and the need for further studies, our data suggests that usage of 
NSAIDs is at odds with current evidence; and is used without professional health advice. Amateur 
athletes need better information about the benefits and potentially serious harms associated with 
NSAIDS.  
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Table 1: Use of NSAIDs by specialism, age, and gender 
  
Discipline Any use for sport related aches and 
pains in the previous 12 months 
Use immediately before, during, or 
immediately after a single bout of 
activity  
Cyclist (N=40) 21 (53%) 7 (33%) 
Triathlete (N=32) 27 (84%) 19 (70%) 
Runner (N=57) 40 (71%) 32 (56%) 
Age      
18-23 (N=38) 24 (63%) 9 (24%) 
24-40 (N=51) 35 (69%) 27 (53%) 
41-60 (N=38) 28 (74%) 21 (55%) 
60+ (N=2) 1 (50%) 1 (50%) 
Gender     
Male (N=89) 58 (65%) 37 (42%) 
Female (N=40) 30 (75%) 21 (53%) 
Total (N=129) 88 (68%) 58 (45%) 
  
  
 
Table 2: Expected NSAID benefits and adverse effects reported by respondents 
  
Expected Benefit NSAID user (n=88) Non-Users (n=41) 
Anti-inflammatory effect 77 (88%) 32 (78%) 
Analgesia 35 (40%) 10 (24%) 
Reduced nausea 7 (8%) 4 (10%) 
Reduced bowel 
movements 
3 (3%) 0 (0%) 
Expected Adverse effect     
Gastrointestinal effects 50 (57%) 17 (42%) 
Gastrointestinal 
bleeding/ulcers  
56 (64%) 27 (66%) 
Kidney impairment 42 (48%) 19 (46%) 
  
  
  
 
